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Introduction
Following cardiac surgery, blood loss and allogeneic 
blood transfusions are associated with increased mor-
tality and morbidity.1–4 Allogeneic blood transfusions 
have a number of risks, including febrile and allergic 
transfusion reactions5 and an increased likelihood of 
severe postoperative infections.6 Although transmission 
of infections such as hepatitis B/C and HIV have been 
virtually eliminated in first world countries through 
blood transfusions,7 inadequate blood screening in 
developing countries has failed to mitigate this consid-
erable risk. Additionally, significant blood transfusion 
costs arise from the need to acquire, process, store and 
administer donated blood products.8 Autotransfusion 
technologies have offered an alternative to transfusion 
and they have been used to salvage and re-transfuse the 
patient’s own blood. Such blood concentration (haemo-
concentration) techniques have included modified dial-
ysis and centrifugation technologies to concentrate cell 
populations and remove excess water and plasma9–11 
and these are relatively complex to use and require spe-
cialist technical knowledge to operate.12 Haemodilution 
strategies during cardiopulmonary bypass (CPB) proce-
dures have adverse effects on fluid balance13 and the sig-
nificant decrease in patient packed cell volume (PCV) 
and haemoglobin is associated with perioperative mor-
bidity and mortality14 and increased blood loss.15
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Background: HemoSep® is a commercial ultrafiltration and haemoconcentration device for the concentration of residual 
bypass blood following surgery. This technology is capable of reducing blood loss in cardiac and other types of “clean 
site” procedures, including paediatric surgery. Clinical feedback suggested that the device would be enhanced by including 
a sensor technology capable of discerning the concentration level of the processed blood product. We sought to develop 
a novel sensor that can, using light absorption, give an accurate estimate of packed cell volume (PCV).
Materials and methods: A sensor-housing unit was 3D printed and the factors influencing the sensor’s effectiveness 
– supply voltage, sensitivity and emitter intensity - were optimised. We developed a smart system, using comparator 
circuitry capable of visually informing the user when adequate PCV levels (⩾35%) are attained by HemoSep® blood 
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HemoSep, a technology developed at the University 
of Strathclyde and manufactured and marketed by 
Brightwake Ltd (Nottingham, UK) is an ultrafiltration 
and haemoconcentration device for the concentration 
of residual bypass blood following surgery. This tech-
nology is capable of reducing blood loss in cardiac and 
other types of “clean site” procedures, including paedi-
atric surgery. HemoSep’s blood bag component uses a 
membrane-controlled superabsorber-driven plasma-
removal process which can preserve all cell species (red 
blood cells, white blood cells, platelets, proteins and 
clotting residuals) and remove contaminants prior to 
re-transfusion. Its control membrane has a pore size 
that prevents migration of cellular species from the 
blood to the superabsorber, whilst allowing free pas-
sage of diluted plasma into the superabsorber. As a 
result, once haemoconcentration to a clinically accept-
able level (a PCV in excess of 35%) is achieved, the con-
centrated blood product is transferred to a transfer bag 
for subsequent autotransfusion. Effective haemocon-
centration is supplemented by placing the HemoSep 
bag on HemoSep’s orbital shaker to agitate the device 
to encourage movement of the cells across the mem-
brane surface and discourage settlement within the 
pore structure. HemoSep efficacy has been demon-
strated clinically using residual diluted bypass and cir-
cuit blood12 and its deployment was also associated 
with reduced postoperative bleeding and red blood cell 
transfusion, as well as a decrease in post-cardiac bypass 
inflammatory response.16
Having launched the HemoSep device into interna-
tional markets, clinical feedback suggested that the 
device would be enhanced by including a sensor technol-
ogy capable of discerning the concentration level of the 
processed blood product. PCV values provide key clini-
cal decision-making data by determining when the 
HemoSep process should be stopped and the blood 
transfused back to the patient. Currently, the only way to 
measure PCV with any accuracy in processed blood is 
to use a manual method, which requires blood samples 
to be taken intermittently from the HemoSep reservoir 
for time-consuming processing and manual estimation 
using hospital laboratory services. Developing a more 
efficient method that will not negatively impact upon 
blood processing time is required to solve this problem. 
The on-line real-time measurement of blood cell con-
centration is a complex issue and is impacted by a num-
ber of factors and there are no devices on the market at 
present that are capable of making accurate PCV meas-
urements under the dynamic conditions represented by 
the HemoSep device. HemoSep’s effectiveness and 
impact would be greatly improved by giving the clinician 
the ability to quantify the concentrated cell products 
within the blood at the point of care while a surgical pro-
cedure is ongoing rather than relying on delivering blood 
samples to a clinical laboratory and waiting a significant 
delayed period of time to obtain blood chemistry test 
results. Various photometry techniques have been used 
to calculate haematocrit, such as dual-wavelength near 
infrared (IR)-photoplethysmography,17 optical coher-
ence tomography,18 Raman spectroscopy19 and spectral 
domain low coherence interferometry,20 which derive 
the quantitative measurement of the reflection or trans-
mission properties of blood as a function of wavelength. 
Automated commercial technologies use absorbance 
spectrophotometry light transmittance through blood to 
calculate the haematocrit, in which the absorbance of 
light by the haemoglobin complex in blood allows for the 
derivation of haematocrit via predefined algorithms.
Aims
We aimed to develop a light sensor system – interfac-
ing with HemoSep’s current system – that is sensitive 
to the range of blood concentration levels seen follow-
ing haemodilution strategies associated with CPB 
deployment. A novel absorbance spectrophotometry 
application is capable of providing on-line, real-time 
PCV measurements during HemoSep blood process-
ing. By configuring and setting an electronic compara-
tor system’s reference voltage that corresponds to a 
clinically relevant threshold PCV using manual PCV 
measurements, we sought to develop a light-emitting 
sensor that can give an accurate and immediate esti-
mate of PCV. This smart system would be capable of 
visually informing the user when adequate PCV levels 
(⩾35%) are attained by HemoSep blood processing 
(thus, indicating that the blood is ready for autotrans-
fusion). This involved;
- Development of a 3D-printed sensor housing for 
integration with the existing HemoSep bag tech-
nology.
- Optimisation of the sensing components to maxi-
mize sensitivity to discrete and relevant PCV 
changes, with a focus on voltage supply, resistor 
values and emitter intensity.
- Utilisation of a comparator circuit to provide vis-
ual feedback that informs the user when blood 
haemoconcentration is complete.
Methods
Blood preparation and PCV analysis
Fresh bovine blood was collected from a local abattoir 
in a sealed container and treated with 10,000 IUs of 
heparin sodium from porcine mucosa (Sigma Aldrich, 
Dorset, UK) in 50ml of 0.9% NaCl. To measure the 
PCV, blood samples were collected in capillary tubes by 
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capillary action and one end was sealed with an inert 
wax. Tubes were spun in a Hawksley 127 haematocrit 
centrifuge (Hawksley and Sons Ltd., Brighton, UK) for 
2 minutes and the PCV was read using a Hawksley 
micro-haematocrit reader. To haemodilute the blood 
samples to the appropriate PCV concentrations, vary-
ing volumes of 0.9% sodium chloride solution was 
added to the blood and the PCV was measured. 
Depending on the measured PCV, additional blood or 
saline was added to acquire the desired PCV for sensor 
assessment. Fifty millilitres of haemodiluted blood was 
collected and 1 ml blood samples were placed in absorp-
tion cell cuvettes with a 5 mm light path for spectral 
analysis (Hellma Analytics, Mullheim, Germany).
Sensing components
Photometry components sensitive to blood haemoglo-
bin (High Power Infrared Emitter (850nm), RS 
Components, Corby, UK and a photodetector (a mono-
lithic photodiode with on-chip trans-impedance ampli-
fier as a light-to-voltage device for wavelengths in the 
range of 300 nm to 1100 nm, RS Components)) were 
selected. The emitter’s voltage output is the product of 
the photodiode current times the feedback resistor and 
the internal feedback resistor is laser trimmed to 1 
megaohm (M:).
Development of a 3D-printed sensor 
housing unit
The sensor housing unit design was drawn using 3D 
computer-aided design (CAD) software (PTC Creo 
Suite, PTC Inc., Needham, MA, USA). A clip-shaped 
prototype was developed to enable a suitable interface 
between the sensor components and the blood samples 
and to allow for integration with the pre-existing 
HemoSep bag. In this proof-of-concept series of exper-
iments, the diagnostic sensor was assessed in a static 
environment, using absorption cell cuvettes that mim-
icked the dimensions and blood volume that we would 
expect to measure under dynamic clinical HemoSep 
blood-processing conditions. Imminent clinical trials 
will allow us to incorporate the sensing technology into 
the hardware of the commercial HemoSep system as 
an adjunct to the core technology in a dynamic setting. 
The housing unit for the sensing technology was 3D 
printed using an EnvisionTEC Perfactory Desktop 
XL printer (EnvisionTEC GmbH, Gladbeck, Germany) 
with Magics software (Materialise, Sheffield, UK). The 
resolution selected for printing was 25 microns and 
parts were printed using HTM140 material, a meth-
acrylic-/acrylic-resin manufactured by EnvisionTEC 
with ABS-like material properties. The clip was designed 
to allow a distance of 8 mm between the emitter and the 
detector. This was a suitable distance that enabled the 
HemoSep bag to securely attach to the clip and it 
allowed for optimisation of the sensing components 
during experimental work by ensuring the absorption 
cell cuvette slots into the clip for blood PCV analysis.
Optimisation of the sensing components
Supply voltage. The sensing technology must be capable 
of detecting and delineating the PCV values through 
the clinically relevant blood range (5-40%). Since the 
sensor converts light readings to a voltage - and voltage 
is proportional to blood concentration - a calibration 
curve of blood concentrations against voltage was gen-
erated to profile the voltage response and to select the 
optimal supply voltage for the technology. Using a DC 
power supply (Digimess PM3006-2, Digimess Instru-
ments Ltd., Derby, UK), calibration curves of PCV 
against voltage response for three voltage outputs (5V, 
10V and 15V) were generated. PCV values in 5% incre-
ments from 5-40% were assessed using 1 ml blood sam-
ples placed in cuvettes in the sensor housing unit and 
the voltage response was acquired via a USB analog 
input channel of a LabView data acquisition (DAQ) 
module (NI USB-6225, National Instruments, Austin, 
TX, USA) and viewed with NI LabVIEW 2013 (National 
Instruments).
External resistor values. The optimal sensitivity for the 
sensing components was defined by assessing the sen-
sor response with a series of fixed resistors. Resistors 
were used to assess how the change in sensitivity would 
affect the linearity of the response and the sensor’s abil-
ity to delineate discrete PCV changes. The gradient of 
the curve was assessed to confirm if this configuration 
was capable of delineating voltage responses through 
the whole 5-45% PCV range and a linear trend-line 
determined optimal resistor selection. Twelve external 
resistor values were selected between 47.84 kiloohms 
(k:) and 720 k:. Based on the profiles generated from 
the 12 resistors, resistors with higher values (between 
470k: and 1000k:) were assessed at PCV values 
between 30% and 45% to focus on resistors sensitive 
enough to delineate voltage responses within this cru-
cial PCV range. For the external resistor measurements, 
a total of 17 resistor values were assessed, ranging from 
47.84 k: to 1000 k:. For the lower resistor values 
(47.84 to 720 k:), nine PCV values ranging from 5% to 
45% were assessed using an average of three blood sam-
ples taken per PCV value (324 blood samples). For the 
higher resistor values (470 to 1000 k:), five PCV values 
ranging from 30% to 43% were assessed using an aver-
age of three blood samples taken per PCV value (75 
blood samples). There was no statistical difference 
between the three samples averaged. All blood samples 
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were gently agitated before placement in the sensor to 
prevent settling of the cells in the cuvette and each sam-
ple was measured immediately and the data plotted. 
The optimal resistor was then selected for inclusion into 
the sensor circuitry and used for subsequent experi-
mental procedures.
Emitter intensity. It was vital to standardise the emitter 
intensity following the assessment of its influence on 
sensor responsivity. Emitter current values were tested 
at 100 milliamps (mA) and 133mA. To calculate the 
resistance required for these current values, the follow-
ing equation was used:
R =
−





Vsupply Vf
i
)
Where Vsupply is 5V, Vf for the emitter is 3V (in accor-
dance with the emitter’s datasheet value) and i is the 
desired current. From this, each current’s resistance 
value was:
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Profiles of the voltage response for PCV values between 
30-45% were assessed using the two selected emitter 
intensities.
Developing a smart system - comparator 
and light-emitting diode (LED) circuit
Following optimisation of all parameters that control 
the sensitivity and emissivity of the sensor technology, 
a comparator circuit was designed and built to provide 
visual response feedback to the end-user. The compara-
tor system used one green and one red light-emitting 
diode (LED) and its premise was that illumination of 
the red LED would be the default configuration when 
the blood is not adequately haemoconcentrated 
(PCV<35%). Experimental work to generate the volt-
age values was carried out to select a reference voltage 
that corresponds to the PCV that we want the blood to 
reach before giving it back to the patient. When a refer-
ence voltage is reached, the red LED will switch off and 
the green LED illuminate to ultimately inform the user 
when the haemoconcentration is complete. We aimed 
to set the comparator’s voltage reference to correspond 
to a PCV of greater than 35%. The reference was defined 
by generating voltage readings for the range of blood 
concentrations between 30 and 42%. One millilitre 
blood samples in cuvettes were placed in the sensor and 
the voltage value for each PCV concentration (30%, 
35%, 38%, 40% and 42%) was measured using the 
LabView DAQ module. Graphs of voltage response 
against time were generated and the reference voltage 
value for the comparator system that corresponded to 
the PCV greater than 35% was selected.
Results
Development of a 3D-printed sensor 
housing unit
The sensor housing unit was 3D printed in a matte black 
material to eliminate light scattering. It was developed 
in two parts to allow the electronic components to be 
housed within the unit (Figure 1). A standard 7-way 
DIN connector was connected to enable attachment to a 
power supply.
Optimisation of the sensing components
Supply voltage. From the analysis of the three selected 
supply voltages, the 5V supply voltage displayed a clear 
linear response and a marked delineation in voltage 
readings throughout the whole PCV range (Figure 2). 
The 7.5V and 10V supply voltages had a saturated volt-
age response in the more diluted PCV values (between 
10 and 20%) and were, thus, incapable of differentiat-
ing between these values. For this reason, the 5V supply 
voltage was selected for subsequent experimental work 
on this sensor technology.
External resistor values. All external resistors measured 
showed a marked delineation in voltage responses in 
low PCV values (5-25%) (Figure 3a). However, steeper 
gradients were observed using the higher resistor values 
of 330.6K: and above. All resistors were incapable of 
providing variable voltage responses at PCV values of 
25-45%. Higher resistor values were then tested on PCV 
samples between 30-43% to identify optimal resistor 
values for higher blood concentrations (Figure 3b) and 
it was observed that the highest resistor values tested 
displayed the greatest voltage delineation at these PCV 
values. The 1000 K: resistor showed the most sensitive 
Figure 1. 3D-printed clip built in two parts to house the 
electronic components.
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response at this PCV range and this was selected for the 
sensor technology.
Emitter intensity. For PCV values between 30-45%, the 
influence of emitter intensity was analysed for the 
100mA and the 133mA values (Figure 4). The acquired 
signal had a near linear response with both current 
values. As expected, the higher current displayed the 
greater voltage response, so the 15: resistor (133 
mA current) was incorporated into the sensing 
technology.
Developing a smart system - comparator 
and LED circuit
Using the 5V power supply, the baseline voltage 
response was 4.23V (Figure 5). Reduction in amplitude 
Figure 2. Sensor voltage responses for the selected blood 
concentration (PCV) values using a (a) 5V, (b) 7.5V and (c) 10V 
power supply.
Figure 3. Voltage response of the sensor using various 
external resistors: a) 12 external resistors between 47.84kΩ 
and 720kΩ at the 5-45% PCV range and b) 5 higher value 
external resistors (between 470 kΩ and 1000 kΩ) at the 
30-43% range. Linear trend-lines were added to ascertain the 
steepest gradient. The highest resistor values tested displayed 
the greatest voltage delineation at these PCV values.
Figure 4. The effect of emitter current on the voltage 
response using PCV values between 30-45%.
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from this baseline corresponded to placement of the 
blood sample in the sensing technology. As the PCV 
increased, the voltage response decreased and it was 
possible to show a measureable difference between the 
voltage values at these blood concentrations. The ref-
erence value for this circuit was set at 1.35V (shown as 
a dashed line in Figure 5) which indicated that the 
blood was greater than 35%. When the concentration 
reached this voltage value, the comparator circuit 
switched the LED from red to green illumination 
immediately and this was capable of informing the 
user that haemoconcentration was complete.
The completed sensor prototype
Figure 6 displays the configuration of the sensor proto-
type integrated with HemoSep’s existing technology.
Discussion
The completed sensor technology works effectively for a 
PCV reference value of >35% and it is consistent through 
a range of blood batches and samples and, since the clip is 
externally fixed, it does not interfere with the activity of 
the HemoSep concentration bag. The prototype is cur-
rently designed for simple connection to a power supply 
(shown by the black and red leads on the black cable). As 
a standard 5V power supply is used for the sensor, future 
iterations of this technology will enable the clip to con-
nect and be powered through HemoSep’s orbital shaker. 
The green and red LEDs that provide the visual user feed-
back will also be integrated into HemoSep’s shaker.
The world market for cell salvage is significant. 
Pioneered in open-heart surgery, it is now practiced in 
orthopaedic and trauma surgery, transplantation and 
renal and hepatic surgeries. The UK has circa 50,000 
open-heart surgical procedures annually and 50% use cell 
recovery. There is an increased recognition of the cost 
and risk associated with the use of donor blood/blood 
components so the cell harvesting market is expected to 
grow. It is anticipated that incorporating sensory devices 
into the HemoSep blood bag will enable significant 
enhancement of the device, both in ease of use and speed 
of detection, for the end-user and will enable a more rapid 
uptake of this technology in clinical practice with a novel 
blood concentration technology aimed for use at the 
point of care. The current device requires blood samples 
to be taken during surgery and sent to the laboratory for 
testing cell concentration. This time-consuming step will 
be eliminated and will enable the equipment to be used 
in a larger variety of applications and open up new mar-
kets, for example, in the field for military/emergency 
procedures. This, also, will create opportunities for re-
designing and extending the product range and potential 
use for portable equipment. This study developed and 
integrated a detection sensor into the product to enable 
accurate data outputs at the point-of-care to facilitate 
surgical decisions in situations where there are high levels 
of blood loss and transfusion using the patient’s own 
“recycled” blood is required. The detection capability is 
able to be incorporated into the hardware of the 
HemoSep device and it is a durable, multi-use adjunct to 
the core technology. This sensor technology will consid-
erably enhance the user experience, enabling clinicians to 
clearly define the end point of the haemoconcentration 
process prior to autotransfusion.
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